Physician profile
Mark Reed
NPI 1477585347
$3,742.42
in general payments reported to CMS, 2019-2025
36 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $164 · 2021: $329 · 2022: $712 · 2023: $560 · 2024: $731 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,788.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $963.49 | 2019-2025 | Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $458.96 | 2019-2025 | Keytruda, Lynparza |
| Eisai INC. | $451.84 | 2019-2025 | |
| Tesaro, INC. | $232.16 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $209.77 | 2019-2025 | Lynparza, Enhertu |
| Ethicon US, LLC | $198.75 | 2019-2024 | Surgiflo Hemostatic Matrix, Echelon Circular |
| Davol INC. | $137.28 | 2019 | |
| Clovis Oncology, INC. | $133.72 | 2019-2020 | |
| Astellas Pharma US INC | $121.26 | 2024 | |
| Seagen INC. | $110.38 | 2022 | |
| Rigel Pharmaceuticals, INC. | $89.44 | 2022-2024 | Rezlidhia, Tavalisse |
| Novartis Pharmaceuticals Corporation | $50.88 | 2023-2024 | Kisqali |
| Daiichi Sankyo INC. | $49.05 | 2021-2025 | Datroway |
| Stryker Corporation | $45.41 | 2022 | |
| Abbvie INC. | $42.55 | 2024-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocompatibles, INC. | $40.03 | 2019 | |
| Genentech USA, INC. | $37.23 | 2019-2022 | |
| Agios Pharmaceuticals, INC. | $29.72 | 2022-2023 | Pyrukynd |
| Genzyme Corporation | $29.58 | 2023 | |
| Tempus Ai, INC | $29.27 | 2024 | Xt Cdx |
| Tersera Therapeutics LLC | $24.91 | 2023 | Zoladex |
| Octapharma USA, INC. | $24.69 | 2019 | |
| Dilon Technologies, INC. | $22.30 | 2025 | Hemoblast Bellows |
| Kyowa Kirin, INC. | $21.19 | 2025 | |
| Geron Corporation | $21.12 | 2024 | Rytelo |
| Immunogen, INC. | $20.23 | 2023 | Elahere |
| Pfizer INC. | $19.87 | 2024 | |
| Adc Therapeutics America, INC. | $19.84 | 2022 | |
| Incyte Corporation | $19.62 | 2023 | Jakafi |
| Myriad Genetic Laboratories, INC. | $18.47 | 2025 | Myrisk |
| Exelixis INC. | $15.48 | 2025 | Cabometyx |
| Coherus Oncology, INC. | $14.98 | 2022 | |
| Intuitive Surgical, INC. | $14.15 | 2019 | |
| Secura Bio, INC. | $13.12 | 2022 | |
| Janssen Biotech, INC. | $11.68 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.